Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De Souza says BNC210 has exceeded blood levels, confirming the group can begin its Phase 2 PTSD clinical trial in the middle of 2021.
Bionomics' positive pharmacokinetic results confirms it can begin second Phase 2 study to treat PTSD
